Hidden Statistical Bias May Have Inflated Immunotherapy Hopes in Mesothelioma Trial
A new analysis shows that post-progression censoring may have generated a misleading survival advantage for nivolumab in second-line mesothelioma, resolving ...
A new analysis shows that post-progression censoring may have generated a misleading survival advantage for nivolumab in second-line mesothelioma, resolving ...
A prospective Phase II trial in Japan found that biweekly gemcitabine plus nab-paclitaxel produced a 47.1 percent response rate and ...
A study of more than 5,000 US patients with HR-positive/HER2-negative metastatic breast cancer found median survival of only 13.5 months ...
A nationwide Turkish cohort study of 53 children with Down syndrome shows that those with Down syndrome-related myeloid leukemia achieved ...
A Taiwanese retrospective study shows that tumor number and MELD score can identify which intermediate-stage hepatocellular carcinoma patients benefit from ...
A new study shows that targeted axillary dissection delivers equivalent recurrence, survival, and mortality outcomes compared with full axillary lymph ...
A real-world study of 526 patients found that paclitaxel liposome combined with anti-HER-2 targeted therapies delivered median overall survival of ...
A Japanese multicenter study of 584 patients has developed a nomogram integrating KRAS mutation status, tumor burden score, nodal metastasis, ...
A network meta-analysis of eight Phase III trials involving 7,127 patients suggests that the PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy ...
A meta-analysis of 39 randomized controlled trials involving 8,399 cancer patients found that early palliative care significantly improves quality of ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine